Founded in San Diego, NovoMedix is a biotechnology company dedicated to developing novel, orally available small molecules aimed at treating fibrotic disorders and certain cancers. The company's core mission is to create therapies that enhance efficacy while minimizing cardiotoxicity. NovoMedix's innovative molecules co-target pathways that offer cardioprotective and synergistic anti-tumor effects, particularly for triple negative breast cancer (TNBC), alongside standard chemotherapies.
Notable affiliates include presentations at significant scientific forums like the American Heart Association (AHA) Scientific Sessions. NovoMedix has garnered attention for its preclinical data on NMX2, showcasing promising therapeutic potential. The company’s achievements in developing first-in-class small molecules have positioned it as a key player in both fibrosis and oncology research, contributing to advancements in medical treatments with a focus on improving patient outcomes.